SecBot SecBot

RXRX

RECURSION PHARMACEUTICALS, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001601830 Artificial IntelligenceBiotech & Drug DiscoveryGenomics & Gene Editing
$3.80 +0.10 (+2.70%)
Oct 26 4:00 PM ET · prev $3.70
Market cap
$2.1B
Mid cap
Consensus
Buy
62% Buy or better · 13 analysts
Median target
$7.00
+84% · range $4.00–10.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.23
1 year
−39.7%
from $6.30 · Oct 27
30 days
+2.7%
from $3.70
52-week range
$2.84–6.30
−40% from high · low Mar 30
Avg volume 20D
31.26M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$1.8M
0 buyers · 5 sellers · since Apr 1
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read BEARISH 12 reports · 90 days
Balance 3 bearish · 0 bullish · 6 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 11/12 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Recursion Pharmaceuticals is offering 61,540,000 shares of Class A common stock at $3.25 per share, raising…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $1.8M.

  • InstitutionsMIXED

    Q2 2026: 36 added (0 new), 25 trimmed or exited.

  • AnalystsBULLISH

    8 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.230 → −$0.229 over 90 days. 0 up, 1 down in 30 days.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD PORTFOLIO MANAGEMENT LLCADD31,131,599$114.3M
UBS Group AGADD8,947,102$32.8M
MARSHALL WACE, LLPADD4,714,577$17.3M
GOLDMAN SACHS GROUP INCTRIM3,917,858$14.4M
MORGAN STANLEYADD2,743,499$10.1M
MILLENNIUM MANAGEMENT LLCTRIM1,834,762$6.7M
Nuveen, LLCADD1,721,154$6.3M
CITIGROUP INCDOUBLED864,403$3.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 62% rate it Buy or better
Strong Buy2Buy6Hold5Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +84%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026Needham
REITERATE
REITERATEBuy
May 14, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
May 7, 2026Needham
REITERATE
REITERATEBuy
Apr 30, 2026JP Morgan
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$1.8M
sold · 5 insiders
DateInsiderTypeValue
Oct 6, 2026
HERSHBERG ROBERT
Director
SELL$125.0K
Oct 6, 2026
HERSHBERG ROBERT
Director
EXERCISE$55.5K
Oct 6, 2026
Borgeson Blake
Director
SELL$242.0K
Oct 1, 2026
Dar Zavain
Director
AWARD4,607 sh
Oct 1, 2026
Li Dean Y
Director
AWARD3,378 sh
Sep 15, 2026
Taylor Ben R
Chief Financial Officer
TAX W/H$18.4K
Sep 8, 2026
Khan Najat
CEO and President
SELL$78.8K
Sep 1, 2026
Borgeson Blake
Director
SELL$100.2K

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.23
EPS estimate, this quarter
+1%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.23-$0.25–-$0.20+0.0%$14.8M
Next Q-$0.22-$0.27–-$0.18-2.3%$14.8M
Current FY🔒 Fresh data, subscribers only
Next FY-$0.87-$1.04–-$0.68+2.7%$53.0M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Earnings
🔒 Fresh data, subscribers only
Oct 15, 2026 SEC
Recursion Pharmaceuticals is offering 61,540,000 shares of Class A common stock at $3.25 per share, raising…
424B5 — Impact 6/10
Oct 15, 2026 SEC
Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at…
8-K — Impact 6/10
Oct 15, 2026 Press
Recursion Pharmaceuticals announced that Sanofi has optioned the first development candidate from their multi-program…
Impact 5/10
Oct 15, 2026 Press
Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per…
Impact 6/10
Oct 15, 2026 SEC
Recursion Pharmaceuticals is filing a preliminary prospectus supplement for a $200 million underwritten public…
424B5 — Impact 6/10
Oct 6, 2026 Insider
HERSHBERG ROBERT sold 25,000 shares
Director @ $5.00 ($125.0K)
Oct 6, 2026 Insider
HERSHBERG ROBERT acquired via exercise 25,000 shares
Director @ $2.22 ($55.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
RXRX Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 26, 2026
Earnings
🔒 Fresh data, subscribers only
Oct 22, 2026
Clinical Trial
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
Phase 2 · COMPLETED
Oct 15, 2026
Contract
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently…
Oct 15, 2026
Announcement
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage…
Oct 15, 2026
FDA
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other…

SecBot reports

16 filings · 5 press releases · 1 bullish · 2 bearish · 5 mixed · 8 neutral
All RXRX filing & press-release reports (21)